Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Best results achieved so far in kidney cancer treatment: lenva and pembro

Best results achieved so far in kidney cancer treatment: lenva and pembro

Kidney cancer has become a cancer type in which new oncological treatments have made a particularly strong impact and firsts have occurred in recent years. After 2000, 9 different targeted cancer drugs and 3 different immunotherapies for kidney cancer received FDA approval. With these advances, the median progression-free (without progression) survival time had increased from 8 months to 17 months. With the results presented at the 2021 Genitourinary Cancers Symposium and simultaneously in NEJM journal, the phase-III CLEAR study impressively extended this duration to 24 months.

According to the results of the CLEAR study, the targeted drug and immunotherapy (lenvatinib plus pembrolizumab) combination was superior to the standard treatment, sunitinib, in terms of overall survival, progression-free survival and objective response rate.

The CLEAR study also included an experimental arm investigating the lenvatinib plus everolimus combination; this arm also outperformed sunitinib for progression-free survival and objective response rate, but did not demonstrate a significant survival benefit. Lenvatinib plus everolimus had received FDA approval for advanced kidney cancer in 2016.

The study presenter, Dr. Robert J. Motzer said: "Lenvatinib plus pembrolizumab significantly improved progression-free survival, overall survival and objective response rate compared with sunitinib for the treatment of patients with advanced clear-cell renal cell carcinoma (kidney cancer). These results support lenvatinib plus pembrolizumab for the treatment of patients with advanced renal cell carcinoma as first-line treatment".

Details of the CLEAR study

The multicenter, open-label, randomized, controlled, phase III CLEAR study is a three-arm study designed to compare lenvatinib plus pembrolizumab with sunitinib, and lenvatinib plus everolimus with sunitinib, as first-line treatment for patients with advanced kidney cancer.

CLEAR is a global study, with approximately 56% of patients treated in Western Europe and North America and approximately 44% treated in other countries. Baseline characteristics were well balanced across the three treatment arms. Approximately three-quarters of the study group had previously undergone nephrectomy (surgery to remove the kidney).

The study randomly assigned 1,069 patients with advanced disease who had not previously received systemic cancer treatment to 3 arms in a 1:1:1 ratio to receive lenvatinib plus pembrolizumab, lenvatinib plus everolimus or sunitinib. The primary endpoint of the study was progression-free survival; key secondary endpoints were overall survival and objective response rate.

Results

The median progression-free (without progression) survival time assessed by independent review was 23.9 months for the lenvatinib plus pembrolizumab arm versus 9.2 months for sunitinib; a 61% improvement in favor of the combination arm ( P <.001).

Lenvatinib plus everolimus also met the primary endpoint, with a median progression-free survival of 14.7 months representing a 35% improvement in favor of this combination ( P <.001).

The progression-free survival benefit of lenvatinib plus pembrolizumab was evident in all subgroups, including all International Metastatic RCC Database Consortium (IMDC) risk groups: favorable, intermediate and low risk.

Lenvatinib plus everolimus also provided benefit versus sunitinib in subgroup analysis, but confidence intervals were wider for this combination, particularly for the poor-risk group.

Below is an indirect comparison of the treatments that have so far received FDA (United States Food and Drug Administration) approval for advanced kidney cancer treatment and the lenvatinib plus pembrolizumab combination tested in the CLEAR study discussed in this article:

kidney cancer treatment comparison of first-line treatments progression-free survival times

An interim overall survival analysis also favored the lenvatinib plus pembrolizumab combination, with a 34% improvement compared with sunitinib ( P = .005). In contrast, there was no difference in overall survival with the lenvatinib plus everolimus and sunitinib combination.

With lenvatinib combinations, response rates were also significantly better. The confirmed objective response rate was 71% with lenvatinib plus pembrolizumab, 53.5% with lenvatinib plus everolimus and 36.1% with sunitinib.

Below is an indirect comparison of the objective response rates of approved treatments for advanced kidney cancer and lenvatinib plus pembrolizumab:

kidney cancer treatment comparison of first-line treatments lenvatinib pembrolizumab objective response rate

Another striking result was the high complete response rate. It was 16.1% with lenvatinib plus pembrolizumab compared with 4.2% with sunitinib. These data represent the best results reported in the treatment of advanced kidney cancer.

The median duration of response was 25.8 months with lenvatinib plus pembrolizumab, 16.6 months with lenvatinib plus everolimus and 14.6 months with sunitinib.

Below is an indirect comparison of the complete response rates of approved treatments for advanced kidney cancer and lenvatinib plus pembrolizumab:

advanced kidney cancer lenvatinib pembrolizumab complete response

Treatment-related grade 3 or higher adverse events occurred in 71.6% of patients in the lenvatinib plus pembrolizumab group, 73.0% in the lenvatinib plus everolimus group and 58.8% in the sunitinib group. Dose reductions and discontinuations due to treatment-related adverse events were more common with lenvatinib combinations than with sunitinib, but adverse events were comparable to those seen in other studies and no new safety signals emerged.

*

Below is a summary of the current state and recent developments in kidney cancer treatments

Sources

R. Motzer, B. Alekseev, S.-Y. Rha, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. NEJM 13 Feb 2021

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Best results achieved so far in kidney cancer treatment: lenva and pembro

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy